

ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 15, No. 12

June 24th, 2016

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association* and membership news. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

- Update on CMS's Medicare Part B drug reimbursement experiment
- Prepare for MACRA now
- PQRS & Meaningful Use deadlines
- ANCO's 2016 Professional Education Meeting
- ANCO's ASCO Highlights 2016

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members. The next regular *ANCO FAX News* will be published on July 8th. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; execdir@anco-online.org.

The *ANCO FAX News* has information for every member of your practice or organization. Pass it along!

- ☐ Physician Members
- ☐ Nurses & Office Managers
- ☐ Office Staff
- ☐ Colleagues & Representatives

The Association of Northern California Oncologists (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge. The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

ASCO is advocating for key cancer care issues at the *American Medical Association (AMA) House of Delegates (HOD)*, including measurement of drug costs to assess resource use under MACRA, opposition to USP800, clinical pathways, and opposition to the CMS Medicare Part B drug reimbursement experiment. The AMA HOD adopted an ASCO-submitted resolution asking CMS to withdraw the Medicare Part B drug reimbursement experiment or alternatively asking Congress to block the experiment from moving forward. **ASCO supports HR5122, legislation that would halt CMS from implementing the CMS Medicare Part B drug reimbursement experiment and helps to keep the pressure on the Administration to withdraw or substantially change the Experiment**, and urges the House to pass it in a timely manner. Please ask your Representative to co-sponsor HR5122 today by visiting cqrcengage.com/asco/.

MACRA redefines how Medicare will reimburse oncologists for care they provide starting in January 2019. However, because evaluation begins in less than six months (i.e., 2017), it is imperative that oncologists understand and prepare for this reimbursement change now. Medicare intends to pay each provider a different fee based on their value and performance. Providers will choose one of two pathways. Providers choosing the *Merit-Based Incentive Payment System (MIPS)* will be paid higher or lower fees for each service provided based on their Composite Performance Score. Providers choosing the *Advanced Alternative Payment Model (APM)* will participate in risk-based programs and receive a 5% bonus. Services provided in 2017 will form the basis for payments in 2019 and the actions you take starting in January 2017 will result in a

reduction of up to 4% or increase of up to 22% in your Medicare revenue in 2019. Go to www.asco.org/practice-guidelines/practice-management-issues/medicare-program/macra for more information. Read Bobbie Buell's analysis of the MACRA proposal at www.anco-online.org/BBMacraAnalysis.pdf. Listen to ACCC's webinar on MACRA at attendee.gotowebinar.com/recording/viewRecording/2308644939852908546/4288900566134237187/execdir@anco-online.org.

MACRA encourages the development of alternatives to the current Medicare fee-for-service payment system as a means to achieve higher quality and more affordable care. ASCO believes that its *Patient-Centered Oncology Payment (PCOP)* model meets MACRA's definition of an alternative payment model (APM) and will actively advance PCOP as a certified APM. ASCO is offering practices a unique opportunity to test PCOP and will provide tools and assistance in modeling data to help practices be successful. To learn more about PCOP, please go to www.asco.org/advocacy-policy/policies-positions-guidance/coverage-reimbursement/physician-payment-reform.

CMS has released an updated transmittal and Medlearn Matters regarding billing for drug waste packaged in a single dose vial. Starting January 1st, 2017 Medicare contractors will require the use of modifier JW to identify unused drugs or biologicals from single use vials or single use packages that are appropriately discarded. This modifier, billed on a separate line, will provide payment for the amount of discarded drug or biological. The only exception to the above is when the J-code is larger than the drug plus the waste. In addition, documentation in the record must reflect the drug given plus the amount of drug wasted; every effort must be made to use drugs "in such a way that they can use drugs or biologicals most efficiently, in a clinically appropriate manner" (i.e., drugs should not be wasted if there are other patients that can use the waste or if there is a smaller vial size); and, this guidance does not apply to multi-dose vials because Medicare does not pay for wasted drug units in this scenario.

Groups of two or more eligible professionals (EPs) can avoid the -2% CY2018 Physician Quality Reporting System (PQRS) payment adjustment by meeting the satisfactory reporting criteria through the 2016 PQRS Group

Reporting Option (GPRO) by June 30th. For more information, go to www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/Payment-Adjustment-Information.html.

Physicians should be aware that July 1st is the extended deadline for physicians to file hardship exception applications from the electronic health record incentive program meaningful use requirements. CMS has released new "streamlined" hardship exception application forms at www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/PaymentAdj_Hardship.html. To help physicians navigate the hardship exceptions process, the *California Medical Association* (CMA) has published *Meaningful Use Hardship Exception Frequently Asked Questions* available at www.cmanet.org/resource-library/detail/?item=meaningful-use-hardship-exception-faqs.

CMA, MOASC, and State Legislative & Regulatory Issues

The *California Oncology Political Action Committee* (or CalCancerPAC), formed by ANCO and MOASC, supports candidates sensitive to the needs of hematologists/oncologists and people living with cancer in California. ANCO membership dues include a contribution to CalCancerPAC.

The *California Cancer Registry* (CCR) has published free materials to help physicians better inform their patients about the *Registry* and **cancer reporting**. A patient information brochure and poster are now available to physicians to distribute to cancer patients at the time of their diagnoses. To obtain copies of the brochure and poster, please visit www.ccrca.org/Inside_CCR/Patient_Information/shtml. CMA's *Requirements for Reporting Cancer and Parkinson's Disease Cases* is available at www.cmanet.org/resource-library/detail/?item=requirements-for-reporting-cancer-and&r_search=3662&r_page=1&return_to=list.

Under California law, all individuals practicing in California who possess both a state regulatory Board license authorized to prescribe, dispense, furnish, or order controlled substances and a Drug Enforcement Administration Controlled Substance Registration Certificate (DEA Certificate) must register for the Controlled Substance Utilization Review and Evaluation

System (CURES) by July 1st. The *California Medical Association* (CMA) recently co-hosted a webinar with the *Department of Justice* (DOJ) to help physicians navigate the CURES 2.0 registration process. The webinar is now available on demand at www.cmanet.org/resource-library/detail/?item=cures-20-navigating-the-states-new0&r_search=&r_page=&return_to=list.

On July 1st, a new law (SB137) will take effect that requires health plans to ensure that physician directories are accurate and up-to-date. The new law also requires physicians to do their part in keeping this information up-to-date. Specifically, the law requires providers to notify payors within five business days if they are no longer accepting new patients or, alternatively, if they were previously not accepting new patients and are now open to new patients. SB137 also requires physicians to respond to plan and insurer notifications regarding the accuracy of their provider directory information, either by confirming the information is correct or by updating demographic information as appropriate. Contact CMA's reimbursement help line at (888) 401-5911 or economicservcies@cmanet.org for more information.

CMA Practice Resources (CPR) is a monthly e-mail bulletin from CMA's Center for Economic Services that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit www.cmanet.org/cpr to subscribe.

Noridian/JEMAC, DHCS/MediCal, & Private Payers

Noridian Administrative Services is the Jurisdiction E (JE) Medicare Administrative Contractor (MAC). Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews *Announcements*—EHR Incentive Program: Hardship Exception Applications Due July 1; CMS to Release CBR on Immunohistochemistry and Special Stains in July; Track and Improve

Your ICD-10 Progress; Medicare Will Use Private Payor Prices to Set Payment Rates for Clinical Diagnostic Laboratory Tests in 2018; HHC Announces Major Initiative to Help Small Practices Prepare for the Quality Payment Program; Quality Payment Program: What's Available Online

Claims, Pricers, and Codes—Chronic Care Management Payment Correction for RHCs and FQHCs

Events—Quality Measures and the IMPACT Act Call-July 7; SNF Quality Reporting Program Call-July 12; Clinical Diagnostic Laboratory Test Payment System Final Rule Call-July 6

Publications—Reading a Professional Remittance Advice Booklet-Reminder

- Coding Revisions to NCDs-Revised CR9631
- New Enrollment on Demand Application Tutorials
- MLN Connects eNews-June 9, 2016
- There is Still Time to Rate Us
- JW Modifier: Drug Amount Discarded/Not Administered to any Patient-Second Revision CR9603
- Avoiding Denials on Priced Per Invoice Claims: Additional Codes-Effective August 15, 2016
- Clinical Diagnostic Laboratory Test Payment System Final Rule Call-Registration Now Open

Noridian/JEMAC's Electronic Data Interchange Support Services (EDISS) invites you to subscribe to its e-mail distribution list to receive current information at www.edissweb.com/cgp/news/index.html.

Forthcoming *Noridian/JEMAC* meetings/workshops include:

- Reopenings (June 29th)
- Recoupment (June 30th)
- Medicare Secondary Payer (July 6th)
- Medicare Secondary Payer Calculation (July 7th)
- NCCI and MUEs (July 12th)
- Telehealth Services (July 14th)
- Ask the Contractor Teleconference (July 20th)

Visit med.noridianmedicare.com/web/jeb/education/training-events for more

information and to register.

Noridian/JEMAC's MAC Satisfaction Indicator Survey is now available online for providers to complete. This survey should only take about 10 minutes of your time and helps *Noridian/JEMAC* understand how to better service you. Complete the *Survey* at med.noridianmedicare.com/web/jeb/article-detail/-/view/10525/evaluate-our-services-in-10-minutes.

Noridian/JEMAC has resumed its regular revalidation cycle and encourages all providers to learn about their revalidation requirements at med.noridianmedicare.com/web/jeb/enrollment/revalidation.

Subscribe today to receive the DHCS/Medi-Cal Subscription Service (MCSS) via e-mail. The MCSS is a free service that can help keep you up-to-date on the latest DHCS/MediCal news. Go to the MCSS Subscriber Form (files.medi-cal.ca.gov/pubsdoco/mcss/mcss.asp) to subscribe.

A list of DHCS/MediCal webinars is at files.medi-cal.ca.gov/pubsdoco/newsroom/newsroom_23149.asp?utm_source=iContact&utm_medium=email&utm_campaign=Medi-Cal%20NewsFlash&utm_content=23149.

EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

ANCO's 2016

Professional Education Meeting

ANCO will host its 2016 professional education meeting on August 3rd at *The Claremont Resort*. An announcement with the agenda and faculty was distributed in early June. The agenda includes *MACRA—What It Is and How Oncology Practices Can Prepare; Managing Oncology within Medicare; California's End of Life Option Act*; and, *An ANCO Practice Atlas—Who We Are, What We Are Doing in Our Practices, and How This Compares to Other Oncology Practices*. The faculty will be Sybil Green, JD, RPh, *Director, Coverage and Reimbursement, ASCO*; Arthur Lurvey, MD, FACP, FACE, *Medicare Contractor Medical Director, Noridian/JEMAC*; Shirley Otis-Green, MSW, ACSW, LCSW, OSW-C, *Clinical Director of Consulting Services, Coalition for Compassionate Care of California*; and, Elaine L. Towle, CMPE, *Director, Analysis and Consulting*

Services, Clinical Affairs Department, ASCO.
Download the meeting announcement and registration form at www.anco-online.org/ProfEduc2016.pdf.

ASCO's Best of ASCO

ASCO's *Best of ASCO* takes place in San Diego on August 12-13th. Visit boa.asco.org for more information and to register.

SAVE THE DATE

ANCO's ASCO Highlights 2016

ANCO's *ASCO Highlights 2016* will take place on Saturday, August 27th at *The Claremont Resort* in Oakland. Faculty from *Stanford University*, the *University of California, Davis*, and the *University of California, San Francisco* will summarize the research and treatment advances reported at ASCO's *Annual Meeting*. A meeting announcement and registration form will be distributed in late June.

Additional Education Meetings

Other meetings of possible interest to ANCO member practices are:

June 28th
Step Therapy and You: How Step Therapy Policies Affect Patient Access to Treatment
California Partnership for Access to Treatment
Sacramento
(<https://www.eventbrite.com/e/step-therapy-you-tickets-25659331752>)

June 28th
Transplantation as a Treatment Option for Blood Cancers
CancerCare
Connect Education Workshop

June 29th
Precision Medicine in Cancer Treatment
CancerCare
Connect Education Workshop

June 30th
Update on Glioblastoma
CancerCare
Connect Education Workshop

July 20th
Triple Negative Breast Cancer and African American Women
CancerCare
Connect Education Workshop

August 4-6th
17th Annual International Lung Cancer Congress
Physicians' Education Resource
Huntington Beach
(www.gotoper.com/conferences/ilc/meetings/17th-International-Lung-Cancer-Congress)

September 16-17th
2016 ASH Meeting on Hematologic Malignancies
American Society of Hematology
Chicago
(www.hematology.org/Malignancies/)

September 21st-22nd
ASCO Advocacy Summit 2016—Lead, Engage, Influence
American Society of Clinical Oncology
Washington, D.C.
(www.asco.org/advocacy/2016-advocacy-summit-capitol-hill)

September 30th
ICLIO National Conference: Immuno-Oncology—There's More to Discover
ACCC's Institute for Clinical Immuno-Oncology
Philadelphia
(accc-icl.io.org/events/iclio-2nd-national-conference/)

October 19th-21st
ACCC 33rd National Oncology Conference: The How-To Conference for the Cancer Care Team
Association of Community Cancer Centers
St. Louis
(www.accc-cancer.org/meetings/NOC2016.asp)

February 9-12th
Practical Recommendations in Immuno & Molecular Oncology (PRIMO)
Maui, Hawaii
(www.primomeeting.org)

Please contact the ANCO office for more information about these meetings.

ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

Board of Directors

The ANCO *Board of Directors* teleconferenced on June 22nd to discuss and/or act upon the following issues:

- CMS Part B drug reimbursement experiment
- California legislation

- AI task force recommendations
- Membership dues task force recommendations
- Future ANCO meetings

Contact the ANCO office for additional information on any of these items.

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The **next regularly scheduled ANCO Board of Directors teleconference is scheduled for August 18th**. Please call José Luis González, *ANCO Executive Director*, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

Individual Member News

A current *Directory of Members* is available online at www.anco-online.org/pubs.html as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at execdir@anco-online.org with any corrections, additions, and/or deletions.

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Annadel Medical Group/St Joseph's Heritage Healthcare, California Cancer Associates for Research and Excellence, Diablo Valley Oncology & Hematology Medical Group, EPIC Care, Pacific Cancer Care, Palo Alto Medical Foundation, and Valley Medical Oncology Consultants* for their multi site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching

universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

*AbbVie • Alexion Pharmaceuticals • AMGEN
ARIAD Pharmaceuticals • Astellas Oncology
AstraZeneca • Bayer Healthcare Pharmaceuticals
Biodesix • Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb Oncology
Cardinal Health Specialty Solutions
Celgene • Clovis Oncology • Daiichi Sankyo
Dendreon • Eisai • Foundation Medicine
Genoptix Medical Laboratory
GenPath Oncology • Genentech BioOncology
Genomic Health • Gilead Sciences
Guardant Health • Helsinn Oncology
Heron Therapeutics • Incyte
Infinity Pharmaceuticals
Ipsen Biopharmaceuticals
Janssen Oncology • Jazz Pharmaceuticals
Lilly Oncology • Merrimack Pharmaceuticals
Medivation • Merck
nanoString • Novartis Oncology
Oncology Supply/ION • Onyx Pharmaceuticals
Pfizer Oncology • Pharmacyclics
Prometheus Laboratories
Sandoz Biopharmaceuticals • Sanofi Genzyme
Sargass Pharmaceuticals Adherence
& Compliance (SPAC) International
Seattle Genetics • Taiho Oncology
Takeda Oncology • Tesaro • TEVA Oncology*

We especially wish to thank and welcome *AbbVie, ARIAD Pharmaceuticals, Biodesix, Clovis Oncology, GenPath Oncology, Guardant Health, Heron Therapeutics, Infinity Pharmaceuticals, Ipsen Pharmaceuticals, Jazz Pharmaceuticals, Merrimack Pharmaceuticals, Prometheus Laboratories, Sandoz Biopharmaceuticals, Taiho Oncology, and Tesaro* as new Corporate Members for 2016. Please visit www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**. ANCO

encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

Lilly Oncology informs ANCO that CMS has assigned C9475 (16mg/ml) to Portrazza with an effective date of April 1st, 2016.

Tesaro informs ANCO that CMS has adopted a *National Coverage Determination* (NCD) outlining when to bill under Medicare Part B versus Part D when using oral anti-emetic therapies. In addition, CMS has established a new Q-code (Q9981; 1mg) for Varubi effective July 1st through December 31st. For dates of service after June 30th, please discontinue the use of Q0181 when billing oral Varubi under Medicare Part B.

Clinical Trial News

ASCO's Research Community Forum (formerly the Community Research Forum) is expanding to have a greater impact on research sites from all types of research settings. The *Forum* is inviting researchers and staff from all types of sites to participate in this unique venue with the aim to advance cancer research and support research program management. The *Forum's* annual meeting takes place at ASCO on September 25-26th. Please visit www.asco.org/research-community-forum to learn more.

Stanford Cancer Center brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- A Phase 2, Prospective Study of PRM-151 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV FM), or Post-Essential Thrombocythemia MF (post-ET MF) [HEMMPD0017; NCT01981850]. Principal Investigator: Jason Gotlib, MD; Contact: Isabel Reyes, (650) 725-4047; ilreyes@stanford.edu
- A Phase I Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral and Subcutaneous Injection in Patients with Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-Type [LYMNH0132; NCT02580552]. Principal Investigator: Youn Kim, MD; Contact: Eric Hong, (650) 725-2142; ekjhong@stanford.edu
- A Phase III Randomized, Double-Blind, Placebo-Controlled Study of LEE011 or Placebo in Combination with Tamoxifen and Goserelin or a Non-Steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal

Women with Hormone Receptor Positive, HER2-Negative, Advanced Breast Cancer [BRS0055; NCT02278120]. Principal Investigator: Suleman Alfred Massarweh, MD; Contact: Janet Pan, (650) 723-0628; panetpan@stanford.edu

- A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease [BMT298; NCT02345850]. Principal Investigator: Lori Muffy, MD; Contact: Janet McDowell, (650) 725-1647; janetm2@stanford.edu

- Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation with or without Infusion of Off-The-Shelf ex vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients with Hematologic Malignancies [BMT291; NCT01690520]. Principal Investigator: Andrew Rezvani, MD; Contact: Physician Referrals, (650) 723-0822

- An Open-Label, Multi-Center, Expanded Access Program for Atezolizumab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma After Failure with Platinum-Containing Chemotherapy [BLDR0021-EXP; NCT02589717]. Principal Investigator: Sandy Srinivas, MD; Contact: Shermeen Poushnejad, (650) 724-7662, shermeen@stanford.edu

- A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Bladder Cancer [BLDR0019; NCT02516241]. Principal Investigator: Sandy Srinivas, MD; Contact: Shermeen Poushnejad, (650) 724-7662, shermeen@stanford.edu

- A Phase I/II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-CD27 antibody (Varlilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors [VAR0132]. Principal Investigator: Branimir I. Sikic, MD; Contact: Rhonda-Lee Aoki, (650) 723-0371, raoki@stanford.edu

- POLO Trial-A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease has not Progressed on First Line Platinum Based Therapy (PANC0018; cancer.stanford.edu/trials/list.html#studyId=NCT02184195). Principal Investigator: James Ford, MD; Contact: Ben Priestley, (650) 723-2990, ben.priestley@stanford.edu

- My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of these Agents [VAR0115; med.stanford.edu/cancer/trials/results.html?ctid=

NCT02091141]. Principal Investigator: James Ford, MD; Contact: Ben Priestley, (650) 723-2990, ben.priestley@stanford.edu

• A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors [NCT02576431]. Principal Investigator: Shivaani Kummur, MD, PhD; Contact: Gagan Grewal, (650) 721-4084; ggrewal@stanford.edu

Publications, Resources, Services, & Surveys

ANCO and MOASC have partnered with SullivanLuallin Group to offer your practice the opportunity to participate in an Oncology-based Patient Satisfaction Survey. The Survey is designed to assess your organization's performance in key areas associated with the ACO and PQRS CAPHS Surveys. SullivanLuallin Group's eSurv: Online Patient Satisfaction Survey platform allows you to efficiently and cost-effectively capture how your patients feel about your systems, services, and performance. Download more information and an enrollment form at www.anco-online.org/PtSurvey2016.pdf.

ANCO and MOASC are jointly conducting a 2016 staff salary survey. The survey was e-mail/FAXed to all members in mid-May and is available online at www.anco-online.org/salsrvy.html. A \$50 Visa gift card for respondents is included in this year's survey. Return your completed survey no later than September 30th; results will be analyzed and reported in 4Q2016.

ASCO's CancerLinQ has launched a new website with expanded information and features for users to meet the needs of patients, practices, donors, researchers, and the larger oncology community. Visit www.CancerLinQ.org to learn more.

ANCO member practices Diablo Valley Oncology & Hematology Medical Group, EPIC Care-Partners in Cancer Care, and Marin Cancer Care are amongst the 58 oncology practices from around the country that have signed agreements to begin implementing CancerLinQ.

ASCO's Clinical Affairs Department is dedicated to providing services, education, and resources to support oncology practices. It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and efficiency and business intelligence to meet the needs and demands of the current oncology landscape. Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are

available from the *Department*. For more information, visit www.asco.org/asco-in-action/asco's-clinical-affairs-department-opens-new-survey-practice-operations.

ASCO's PracticeNET is a collaborative network in which practices share and receive insights to enhance their business operations and quality of care. PracticeNET is the first initiative of ASCO's *Clinical Affairs Department*. This new initiative uses existing data from your practice management system to offer customizable reports that measure practice-wide and individual performance against a national database of other PracticeNET participants. Go to www.asco.org/PracticeNET for more information.

The June 2016 issue of ASCO's Journal of Oncology Practice (JOP) is available online and features articles entitled *Using Quality-Adjusted Life-Years in Cost-Effectiveness Analyses: Do Not Throw Out the Baby or the Bathwater; A Pathway Through the Bundle Jungle; Challenges With Research Contract Negotiations in Community-Based Cancer Research; The Patient Care Connect Program: Transforming Health Care Through Lay Navigation; Patient Navigation As a Model to Increase Participation of African Americans in Cancer Clinical Trials; and, Effectiveness of a Survivorship Program: An Assessment of Patients with Breast Cancer in a Community Setting*. Visit jop.ascopubs.org for more information.

ASCO has issued a series of guidelines on the management of all stages of pancreatic cancer at www.asco.org/practice-guidelines/quality-guidelines/guidelines/gastrointestinal-cancer.

CMS has approved ASCO's Quality Oncology Practice Initiative (QOPI) as a qualified clinical data registry (QCDR), a pathway for oncologists to meet the agency's current quality reporting requirements. Oncology practices registered with QOPI will have the opportunity to fulfill CMS's PQRS or QCDR reporting requirements through QOPI. QOPI is designed to promote excellence in cancer care by helping oncologists create a culture of self-examination and improvement. ASCO offers the *QOPI Certification Program* to recognize QOPI participants who achieve rigorous standards for cancer care. The *QOPI Certification* designation can be used by certified practices to demonstrate an advanced commitment to quality and are eligible to receive a discount of up to 10% on medical malpractice rates from *The Doctors Company*, the nation's largest physician-owned medical malpractice

insurer. Go to www.instituteforquality.org/qopi-qcp for more information.

ACCC has launched an online community to support *Oncology Care Model* (OCM) practices as part of the ACCC OCM Collaborative, a broader effort to support OCM practices throughout implementation of CMMI's first oncology-specific payment reform model. Please contact Leah Ralph, ACCC *Director of Health Policy*, at lralph@accc-cancer.org for more information.

ACCC's new education initiative, *Achieving Excellence in Patient-Centered Care*, will provide cancer programs with tools and resources to identify the key pillars of patient-centric care, measure their effectiveness within each pillar, and ultimately implement or improve their effectiveness in delivering patient-centered care. To inform the project, ACCC has launched a survey to hear how your program provides patient-centered care, measures and tracks its progress, and what types of tools and resources would help support your ongoing patient-centered cancer care assessment and improvement efforts. Take the survey at www.surveymonkey.com/r/?sm=yqdP6e9147ILbmWqKK5A_3D_3D.

ACCC's online *Oncology Drug Database* provides quick access to information on oncology drug coding, billing, and reimbursement at www.accc-cancer.org/drugdatabase/.

ACCC's enhanced set of *Financial Advocacy Network* resources are at www.accc-cancer.org/resources/FinancialAdvocacy-Overview.asp. This "one-stop" destination for comprehensive financial advocacy information includes online training materials, practical financial advocacy tools, peer-to-peer networking, and more.

ACCC's 2016 *Patient Assistance and Reimbursement Guide* is an essential tool for cancer program staff to use in helping patients with issues related to the cost of treatment and in meeting reimbursement challenges. The *Guide* features a list of pharmaceutical and non-pharmaceutical patient assistance programs (PAPs), including directions on how to apply and links to enrollment forms. New for 2016 are tips for optimizing co-pay assistance programs and new financial advocate skills for the the new healthcare environment. Visit www.accc-cancer.org/publications/pdf/Patient-Assistance-Guide-2016.pdf to access this resource. In addition, ACCC has developed a tool for

accessing patient assistance and reimbursement programs for use on a desktop, table, or mobile device. The *Financial Advocacy Network* (FAN) app is available at accc-fan-app.org. ASH also has a webpage (at www.hematology.org/Clinicians/Drugs/Programs/) that provides a consolidated list of resources for hematologists and patients trying to access high cost hematologic drugs. And, at NCCN's *Reimbursement Resource Room* (www.nccn.org/reimbursement_resource_room/default.asp) you can select a cancer diagnosis or supportive care indication and learn about reimbursement help and services available to you. Finally, *assistPoint* is your website for complimentary one-stop cancer Patient Assistance. You can search by generic, brand name, manufacturer, or diagnosis for the enrollment forms you need; get enrollment form PDFs for 113 cancer drugs; get NDC numbers for all of those drugs; find the HCPCS J-code for each drug; get coding and billing guidelines for many drugs; and, learn more about the drugs you give. Go to www.assistpoint.com to learn more.

NCCN has updated their *Clinical Practice Guidelines in Oncology* and/or *Drugs & Biologics Compendium* for Hodgkin lymphoma (V3.2016), prostate cancer (V2.2016), cervical cancer (V1.2016), malignant plural mesothelioma (V3.2016), and thymomas and thymic carcinomas (V3.2016).

Individual Membership Dues for 2016

Final notices of membership renewal for 2016 were mailed in early May. If you have not yet done so, then please return your 2016 membership dues to ANCO now to ensure your inclusion in *The ANCO Directory of Members*. Be sure to provide ANCO with your e-mail address and the name(s) and e-mail address(es) of office and/or nurse manager contact(s). Those not renewing their membership by June 30th will be deleted from the *Directory of Members*, and will no longer be eligible for any ANCO benefits. Contact the ANCO office if you do not receive or misplaced your membership dues renewal notice.

ANCO seeks new members. **All members of a practice should join ANCO.** And, ANCO seeks to enroll radiation oncologists as members, so please send us contact information for the radiation oncologists within your practice and/or to whom you refer patients.

Remember, a larger ANCO is a stronger ANCO!